High Efficiency
Oral Semaglutide
Efficient Weight Loss
Coming Soon
Oral semaglutide delivers the same proven GLP-1 molecule as Wegovy and Ozempic in a once-daily pill — FDA-approved for diabetes, used off-label for weight management.
No needles. Daily dosing.
Oral semaglutide (Rybelsus) is the same proven GLP-1 molecule as Ozempic and Wegovy, but delivered as a once-daily pill. It uses absorption-enhancing technology (SNAC) to enable oral bioavailability — eliminating the need for weekly injections.
Modest weight loss benefit
Rybelsus is FDA-approved for type 2 diabetes at doses up to 14mg daily. In diabetes trials, patients lost an average of 3.8 kg (8.4 lbs). Some providers use higher doses off-label for weight loss (achieving 5–8%), but injectable semaglutide remains significantly more effective.
Same pathway as injectables
Oral semaglutide activates the same GLP-1 receptor as injectable formulations — slowing gastric emptying, reducing hunger, and improving glucose metabolism. The mechanism is identical; the difference lies in bioavailability and dosing frequency.
The Science, in Full Detail
We believe patients deserve to understand exactly how and why their treatment works.
Same molecule. Oral delivery.
Oral semaglutide (Rybelsus) is chemically identical to injectable semaglutide (Ozempic/Wegovy). The difference is delivery: it's co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), an absorption enhancer that protects semaglutide from digestive breakdown and facilitates GI absorption.
Get StartedGLP-1 Pathway
- Slows gastric emptying — food moves through your stomach more slowly, extending fullness
- Signals the brain's satiety centers to reduce hunger and 'food noise'
- Stimulates insulin release in a glucose-dependent, safe manner — no risk of hypoglycemia
- Reduces glucagon secretion, preventing inappropriate blood sugar spikes
- Improves endothelial function and reduces inflammation — direct cardiovascular benefits
Full Transparency
Side effects, honestly
We believe informed patients get better outcomes. Here's exactly what clinical trials report — with context on how common each effect is and how to manage it.
Nausea
Very CommonSeverity: Mild–Moderate
Most common in first 4–8 weeks. Typically resolves as the body adapts. Eating smaller portions and avoiding high-fat foods helps significantly.
Constipation
CommonSeverity: Mild
Slowed GI transit is common with GLP-1 agonists. Increasing water, fiber, and activity level helps normalize bowel function.
Vomiting
CommonSeverity: Mild–Moderate
Most common at initiation and dose escalation. Providers can slow titration pace to minimize this effect.
Decreased Appetite
Very CommonSeverity: Intended effect
This is the primary therapeutic mechanism. Providers monitor to ensure adequate protein and nutrient intake is maintained.
Fatigue
CommonSeverity: Mild
Usually transient, often in the first weeks after dose increases. Ensuring sufficient caloric intake helps.
Diarrhea
CommonSeverity: Mild
Often transient during dose escalation. Stay well-hydrated and consider fiber supplementation.
Questions about Oral Semaglutide
Detailed answers to the most important questions
Transparent Pricing
Consultation Fees
Physician-guided care with complete pricing clarity.
Generic Consultation
Includes Any & All Services
First Visit
$400
Follow-Up
$150
- Complete health assessment
- All service areas covered
- Personalized treatment plan
- Prescription if appropriate
Specialized Consultation
Skin, Hair, Wellness, Labs, Galleri
First Visit
$300
Follow-Up
$150
- Focused specialty review
- Lab analysis included
- Targeted treatment approach
- Follow-up protocol
Peptide Consultation
Weight loss & metabolic therapies
First Visit
$50
Follow-Up
$30
- Metabolic assessment
- GLP-1 or peptide evaluation
- Dosing strategy
- Prescription included